Barcelona Science Park announces a new artistic intervention contest to decorate an outdoor space Blog Post

Barcelona Science Park (PCB) announces a new artistic intervention contest to promote the interaction between art and science. The public and anonymous event offers the opportunity to create, with total thematic freedom, a mural in an outdoor space of 4.5 metres of height per 6.5 metres of width in the Clúster II building, in a junction of various areas of the park at different levels.

 

Juan Carlos Kaski, new Chief Medical Officer of GlyCardial Diagnostics Blog Post

GlyCardial Diagnostics, based in the Barcelona Science Park, announces the appointment of Prof. Juan Carlos Kaski as Chief Medical Officer. The company –a spinoff of the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR-HSCSP) and the Spanish National Research Council (CSIC), is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia.

 

Chemotargets opens an investment round to enter a new phase of growth Blog Post

Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, begins a phase of transformation to expand its activity in the drug discovery sector as a biotechnology company. The company, based in the Barcelona Science Park, is opening an investment round to undertake the transformation of its business model, with tadvice and support of GENESIS Biomed, also located in the Park, and CREA Inversión. 

 

The PCB’s scientific community joins the fight against SARS-CoV-2 Blog Post

In response to the health emergency caused by SARS-CoV-2, research centres and biotech companies in the Barcelona Science Park (Parc Científic de Barcelona, PCB) are leading scientific progress in the treatment, vaccination and diagnosis of the novel coronavirus. The PCB will ensure that public centres and businesses can continue with their research projects by providing the resources and services they need.

 

Dreamers Startup Ventures signs an agreement to invest up to $1.1M in Oncoheroes Biosciences Blog Post

Dreamers Startup Ventures has committed to invest up to $1.1M in Oncoheroes Biosciences, a biotech company exclusively focused on the development of innovative medicines to treat cancer in children and adolescents. Oncoheroes was co-founded by Ricardo Garcia and Cesare Spadoni, two parents touched by childhood cancer and determined to change the outlook for these young patients. Founded at Boston, the company has the European headquarters at the Barcelona Scientific Park where its discovery lab looks for novel targets and molecules.

 

Nostrum Biodiscovery wins the 2019 of Senén Vilaró Prize for best innovative company Blog Post

Nostrum Biodiscovery (NBD), located at the Barcelona Science Park, has won the “2019 Senén Vilaró Prize for best innovative company”, one of the four awards conferred by the Board of Trustees of the University of Barcelona (UB) and the Bosch i Gimpera Foundation (FBG). The ceremony for the awards was held yesterday at the Aula Magna of the Historical Building of the UB.

 

Droplite gets €236,000 from the Neotec programme and the European Commission’s Seal of Excellence Blog Post

DROPLITE, a spin-off from the Institute of Photonic Sciences (ICFO) located in the Barcelona Science Park (PCB), has won a €236,000 grant from the Centre for the Development of Industrial Technology (CDTI) in the latest NEOTEC. The company has also earned the European Commission’s Seal of Excellence, which is awarded to start-ups that have first-class innovation ideas with great potential to open up new markets.

 

Aerie Pharmaceuticals announces agreement to acquire Avizorex Pharma for $10 Million Blog Post

La farmacèutica Aerie Pharmaceuticals, que cotitza al Nasqad, ha annunciat l’adquisició d’Avizorex Pharma (AVX Pharma), amb seu al Parc Científic de Barcelona, per un import de 10 millones de dòlares. La companyia, fundada l’any 2013 com a spin-off de la Universitat Miguel Hernandez de Elche (UMH) per l’emprenedor Patrick Tresserras i el professor Carlos Belmonte de l’Institut de Neurociencias (UMH -CSIC), està especialitzada en el desenvolupament de teràpies innovadores per a la síndrome d’ull sec.

 

TMB Foundation colaborates with Aromics to combat the effects of health arising from asbestos Blog Post

TMB Foundation developed over the coming weeks various activities to raise awareness of the harmful effects of asbestos exposure to human health, in collaboration with the biotech company Aromics Biotech –based in the Barcelona Science Park– and other specialized organizations. This has been the cause of social chosen by company employees, who every year are the protagonists, with their proposals and its vote of solidarity program Choose your cause.